1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
  Report
Delayed Nasdaq Copenhagen  -  08:05 2022-06-28 am EDT
52.80 DKK   +0.76%
06/22ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023
CI
06/21VIROGATES A/S : The nonspecific prognostic biomarker suPAR successfully predicts all-cause 30-day mortality in all age groups.
PU
06/20Invitation to ViroGates' investor meeting
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2022

05/04/2022 | 06:07am EDT

ViroGates A/S reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was DKK 3.2 million compared to DKK 2.08 million a year ago. Net loss was DKK 2.97 million compared to DKK 4.27 million a year ago.


© S&P Capital IQ 2022
All news about VIROGATES A/S
06/22ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023
CI
06/21VIROGATES A/S : The nonspecific prognostic biomarker suPAR successfully predicts all-cause..
PU
06/20Invitation to ViroGates' investor meeting
AQ
06/15ViroGates announces an offering of new shares with pre-emptive rights for existing shar..
AQ
06/15VIROGATES A/S : SuPAR as a Prognostic Marker of Ugandan Children at Risk of Severe and Fat..
PU
05/30ViroGates announces the election of Patrik Dahlen as its new chairman of the board
AQ
05/30ViroGates A/S Announces Board Changes
CI
05/25ViroGates announces the CE-IVD accreditation of its finger-prick blood-testing product,..
AQ
05/25ViroGates Announces the CE-Ivd Accreditation of Its Finger-Prick Blood-Testing Product,..
CI
05/10VIROGATES : Healthy growth
AQ
More news
Financials
Sales 2021 7,66 M 1,09 M 1,09 M
Net income 2021 -17,7 M -2,52 M -2,52 M
Net cash 2021 14,9 M 2,12 M 2,12 M
P/E ratio 2021 -25,7x
Yield 2021 -
Capitalization 166 M 23,7 M 23,7 M
EV / Sales 2020 41,3x
EV / Sales 2021 57,6x
Nbr of Employees 14
Free-Float 52,3%
Chart VIROGATES A/S
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
Patrik Olof Dahlén Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VIROGATES A/S-63.61%25
EXACT SCIENCES CORPORATION-41.99%7 944
GUARDANT HEALTH, INC.-53.76%4 714
BGI GENOMICS CO., LTD.-21.31%4 174
IOVANCE BIOTHERAPEUTICS, INC.-45.78%1 627
VERACYTE, INC.-44.81%1 625